Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).
According to National Institutes of Health (NIH), idiopathic pulmonary fibrosis is a progressive lung disorder characterized by scarring of the lungs from an unknown cause.
The Phase 1b study is designed to evaluate LTI-03 in patients recently diagnosed with IPF that have not received prior treatment with anti-fibrotic agents for at least two months. Topline data from cohort 2 of the study showed that treatment with LTI-03 reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts. The data supported the potential of LTI-03 in reducing fibrosis, inflammation and associated functional changes in the lung.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.